JPMorgan Starts Alder Biopharm (ALDR) at Overweight
- Wall St. rises amid robust GDP data, mixed earnings
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
JPMorgan initiated coverage on Alder Biopharm (NASDAQ: ALDR) with an Overweight rating and a price target of $40.00.
Shares of Alder Biopharm closed at $31.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alder BioPharma (ALDR) Tops Q3 EPS by 15c
- JPMorgan Downgrades Mead Johnson Nutrition (MJN) to Neutral
- Chardan Capital Markets Starts Astrotech Corporation (ASTC) at Buy
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!